Avalyn Pharma Inc. (AVLN)
NASDAQ: AVLN · Real-Time Price · USD
29.76
-0.52 (-1.72%)
Nov 16, 2026, 4:00 PM EST - Market closed

Avalyn Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Net Income
-109.39-85.2-49.74
Depreciation & Amortization
0.290.040.08
Loss (Gain) From Sale of Assets
--0.05
Loss (Gain) From Sale of Investments
-2.1-2.35-2.58
Stock-Based Compensation
7.963.272.47
Other Operating Activities
0.550.15-
Change in Accounts Payable
-0.871.40.23
Change in Other Net Operating Assets
-2.921.221.13
Operating Cash Flow
-106.44-81.48-48.37
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Capital Expenditures
-0.91-0.34-0.1
Investment in Securities
-105.610.4-91.38
Investing Cash Flow
-106.5110.06-91.47

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Issuance of Common Stock
320.880.020.05
Other Financing Activities
-5.03-0.59-
Financing Cash Flow
330.899.790.09

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Net Cash Flow
117.8528.36-139.75

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Free Cash Flow
-107.35-81.83-48.46
Free Cash Flow Growth
---
Free Cash Flow Per Share
-5.58-84.27-179.40
Levered Free Cash Flow
--50.58-
Unlevered Free Cash Flow
--50.58-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Change in Working Capital
-3.792.611.36
SEC Filings: 10-K · 10-Q